Skip to main content
SpringerLink
Log in

Introduction to Diabetes

Principles of Care in the Surgical Patient With Diabetes

  • Chapter
The Diabetic Foot

Part of the book series: Contemporary Diabetes ((CDI))

Abstract

The medical and surgical management of foot disorders in the patient with diabetes should have as its basis a thorough understanding of the complications and metabolic consequences of diabetes mellitus. This is especially true in the patient who is undergoing a surgical procedure. Diabetes is rapidly increasing in prevalence worldwide and surgery in patients with diabetes is more common. Foot complications are already a major cause of admissions for diabetes, and comprise a disproportionately high number of hospital days because of increased surgical procedures and prolonged length of stay.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes, in Diabetes in America (Harris MI, ed.). National Institute of Health, Washington, DC, 1995, pp. 37–46.

    Google Scholar 

  2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76–79.

    Article  PubMed  Google Scholar 

  3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired glucose tolerance in US adults. The third National Health and Nutrition Examination Survey, 1988–1994, Diabetes Care 1998;21:518–524.

    Article  PubMed  CAS  Google Scholar 

  4. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology—from the west to the rest. Diabetes Care 1992;15:232–252.

    PubMed  CAS  Google Scholar 

  5. Neel JV. Diabetes Mellitus: a “thrifty”; genotype rendered detrimental by “progress”;? Am J Hum Genet 1962;14:353–362.

    PubMed  CAS  Google Scholar 

  6. Expert Committee for the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197.

    Google Scholar 

  7. Harris MI. Prevalence of retinopathy since time of diagnosis of type 2 diabetes: WESDR study, 1980–1988, Consultant 1997;37(Suppl):S9–S14.

    Google Scholar 

  8. Turner R, Stratton I, Horton V, et al. UKPDS25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288–1293.

    Article  PubMed  CAS  Google Scholar 

  9. Eisenbarth GS. Type I diabetes mellitus—a chronic autoimmune disease. N Engl J Med 1986;314:1360–1368.

    Article  PubMed  CAS  Google Scholar 

  10. Coutant R, Carel JC, Timsit J, Boitard C, Bougneres P. Insulin and the prevention of insulin-dependent diabetes mellitus. Diabetes Metab 1997;23(Suppl 3):25–28.

    PubMed  CAS  Google Scholar 

  11. Eisenbarth GS. Lilly lecture 1986, genes, generator of diversity, glycoconjugates and autoimmune beta-cell insufficiency in type I diabetes. Diabetes 1987;36:355–364.

    PubMed  CAS  Google Scholar 

  12. Dalhquist GG. Primary and secondary prevention strategies of pre-type 1 diabetes. Potentials and pitfalls. Diabetes Care 1999;22(Suppl 2):B4–B6.

    Google Scholar 

  13. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth Diabetes Care 1999;22:345–354.

    Article  PubMed  CAS  Google Scholar 

  14. Gulli G, Ferrannini E, Stern M, Haffner S, DeFonzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992;41:1575–1586.

    Article  PubMed  CAS  Google Scholar 

  15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223.

    PubMed  CAS  Google Scholar 

  16. DeFronzo RA. Lilly Lecture 1987, the triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–687.

    PubMed  CAS  Google Scholar 

  17. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794.

    PubMed  CAS  Google Scholar 

  18. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318–368.

    Article  PubMed  CAS  Google Scholar 

  19. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 1995;18:225–260.

    Google Scholar 

  20. Buse JB, Polonsky KS. Diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, and hypoglycemia, in Principles of Critical Care Medicine (Hall JBM, Schmidt GA, Woods LDH, eds). 2nd ed., McGraw Hill, New York, 1998, pp. 1183–1193.

    Google Scholar 

  21. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases, Medicine 1972;51:73–94.

    Article  PubMed  CAS  Google Scholar 

  22. Buse JB. The patient with Diabetes, in Management of Office Emergencies (Barton CW, ed.) McGraw Hill, New York, 1999, pp. 73–95.

    Google Scholar 

  23. Cranston I, Lomas J, Maran A, MacDonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283–287.

    Article  PubMed  CAS  Google Scholar 

  24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  25. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986;80:443–453.

    Article  PubMed  CAS  Google Scholar 

  26. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599–606.

    Article  PubMed  CAS  Google Scholar 

  27. Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995;18:275–281.

    PubMed  CAS  Google Scholar 

  28. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–497.

    PubMed  CAS  Google Scholar 

  29. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859–866.

    Article  PubMed  CAS  Google Scholar 

  30. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625.

    Article  PubMed  CAS  Google Scholar 

  31. Krolewski AS, Warram JH, Rand Li, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317:1390–1398.

    Article  PubMed  CAS  Google Scholar 

  32. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.

    Article  PubMed  CAS  Google Scholar 

  33. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25(2):111–118.

    Article  PubMed  Google Scholar 

  34. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care 2004;27(Suppl 1):S84–S87.

    Article  PubMed  Google Scholar 

  35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  36. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986;80:443–453.

    Article  PubMed  CAS  Google Scholar 

  37. Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998;54:1390–1391.

    Article  PubMed  CAS  Google Scholar 

  38. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and diabetes. N Engl J Med 1989;321:1074–1079.

    Article  PubMed  CAS  Google Scholar 

  39. Diabetic nephropathy, ADA position statement. Diabetes Care 2000;23(Suppl 1):S69–S72.

    Google Scholar 

  40. UK Prospective Diabetes Study. Tight blood pressure control and risk of macrosvascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.

    Google Scholar 

  41. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study. J Am Med Assoc 1994;271:275–279.

    Article  CAS  Google Scholar 

  42. American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 2005;28:S4–S36.

    Article  Google Scholar 

  43. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. 1999;892:25–44.

    CAS  Google Scholar 

  44. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473–486.

    PubMed  CAS  Google Scholar 

  45. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary, NIH Publication No. 01-3670, May 2001.

    Google Scholar 

  46. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221–228.

    Article  PubMed  CAS  Google Scholar 

  47. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975–980.

    PubMed  CAS  Google Scholar 

  48. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601–2610.

    PubMed  CAS  Google Scholar 

  49. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior MI. N Engl J Med 1998;339:229–234.

    Article  PubMed  CAS  Google Scholar 

  50. The bypass angioplasty revascularization investigation (BARI) investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217–225.

    Article  Google Scholar 

  51. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21(Suppl):C35–C38.

    PubMed  Google Scholar 

  52. Haffner SM. Management of dyslipidemia in adults with diabetes (technical review). Diabetes Care 1998;21:160–178.

    Article  PubMed  CAS  Google Scholar 

  53. American Diabetes Association. Dyslipidemia management in adults with diabetes, position statement. Diabetes Care 2004;27(Suppl 1):S68–S71.

    Google Scholar 

  54. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160–178.

    Article  PubMed  CAS  Google Scholar 

  55. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy—thrombolysis in MI 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495–1504.

    Article  PubMed  CAS  Google Scholar 

  56. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685–696.

    Article  PubMed  CAS  Google Scholar 

  57. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute. American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227–239.

    Article  PubMed  Google Scholar 

  58. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes, UKPDS39. BMJ 1998;317:713–720.

    Google Scholar 

  59. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.

    Article  Google Scholar 

  60. American Diabetes Association, Hypertension management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S65–S67.

    Google Scholar 

  61. Consensus Development Conference on the Diagnosis of Coronary Heart Disease and Diabetes, 10–11 February 1998, Miami, Florida, American Diabetes Association. Diabetes Care 1998;21:1551–1559 (review).

    Article  Google Scholar 

  62. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabetic Medicine 1994;11:137–144 (review).

    PubMed  CAS  Google Scholar 

  63. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival MI in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Glucose Infusion in Acute MI) Study Group. BMJ 1997;314:1512–1515.

    PubMed  CAS  Google Scholar 

  64. Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 2004;5(3):189–197.

    Article  PubMed  CAS  Google Scholar 

  65. Nissen SE. Application of intravascular ultrasound to characterize coronary artery diseaseand assess the progression or regression of atherosclerosis. Am J Cardiol 2002;89(4A):24B–31B.

    Article  PubMed  Google Scholar 

  66. Harpaz D, Gottlieb S, Graff E, Boyko V, Kishon Y, Behar S. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998;105:494–499.

    Article  PubMed  CAS  Google Scholar 

  67. American Diabetes Association Consensus Statement: peripheral arterial disease in people with diabetes. Diabetes Care 2003;36:3333–3341.

    Google Scholar 

  68. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996;45: 1289–1298.

    Google Scholar 

  69. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:851–853.

    Article  Google Scholar 

  70. American Diabetes Association. Standards of medical care for patients with diabetes mellitus, position statement. Diabetes Care 2005;28:S4–S36.

    Article  Google Scholar 

  71. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996;19:324–327.

    Article  PubMed  CAS  Google Scholar 

  72. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;31:281–303.

    Google Scholar 

  73. UK Prospective Diabetes Study. Effect of intensive blood-glucose control with metformin on complications in overweight patient with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.

    Article  Google Scholar 

  74. Turner R. Stratton I, Horton V, et al. UKPDS25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288–1293.

    Article  PubMed  CAS  Google Scholar 

  75. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49), UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999;281:2005–2012.

    Article  CAS  Google Scholar 

  76. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294–1301.

    Article  PubMed  CAS  Google Scholar 

  77. Spiegelman BM. PPAR-[gamma]: adipogenic regulator and thiazolizinedione receptor. Diabetes 1998;47:507–514.

    Article  PubMed  CAS  Google Scholar 

  78. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119–124.

    Article  PubMed  CAS  Google Scholar 

  79. Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607–615.

    Article  PubMed  CAS  Google Scholar 

  80. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):10, 92–100.

    Article  Google Scholar 

  81. Manske CL, Spraka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615–620.

    Article  PubMed  CAS  Google Scholar 

  82. Tooke JE. Microvascular function in human diabetes: a physiological perspective. Diabetes 1995;44:721–726.

    Article  PubMed  CAS  Google Scholar 

  83. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior MI. N Engl J Med 1998;339:229–234.

    Article  PubMed  CAS  Google Scholar 

  84. Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997;127:313–328.

    PubMed  CAS  Google Scholar 

  85. Hood DB, Weaver FA, Papnicolaou G, Wadhawani A, Yellin AE. Cardiac evaluation of the diabetic patient prior to peripheral vascular surgery. Ann Vasc Surg 1996;10:330–335.

    Article  PubMed  CAS  Google Scholar 

  86. Fleisher LA, Eagle KA. Screening for cardiac disease in patients having noncardiac surgery, Ann Intern Med 1996;124:767–772.

    PubMed  CAS  Google Scholar 

  87. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: an abridged version of the report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Mayo Clin Proc 1997;72:524–531.

    PubMed  CAS  Google Scholar 

  88. Cohen MC, Curran PJ, L’Italien GJ, Mittleman MA, Zarich SW. Long-term prognostic value of preoperative dipyridamole thallium imaging and clinical indexes in patients with diabetes mellitus undergoing peripheral vascular surgery. Am J Cardiol 1999;83:1038–1042.

    Article  PubMed  CAS  Google Scholar 

  89. Zarich SW, Cohen MC, Lane SE, et al. Routine perioperative dipyridamole 201T1 imaging in diabetic patients undergoing vascular surgery. Diabetes Care 1996;19:355–360.

    Article  PubMed  CAS  Google Scholar 

  90. Mangano DT. Assessment of the patient with cardiac disease: an anesthesiologist’s paradigm. Anesthesiology 1999;91:1521.

    Article  PubMed  CAS  Google Scholar 

  91. McFalls EO, Ward HB, Moritz TE, et al. Coronary—artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795–2804.

    Article  PubMed  CAS  Google Scholar 

  92. Guidelines and indicators for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force or Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1991;17:543–589.

    Article  Google Scholar 

  93. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The bypass angioplasty revascularization investigation (BARI) investigators. N Engl J Med 1996;335:217–225.

    Article  Google Scholar 

  94. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and MI in high-risk patients undergoing vascular surgery. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. N Engl J Med 1999;341:1789–1794.

    Article  PubMed  CAS  Google Scholar 

  95. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after non cardiac surgery. N Engl J Med 1996;335:1713–1720.

    Article  PubMed  CAS  Google Scholar 

  96. Monahan TS, Shrikhande GV, Pomposelli FB, et al. Preoperative cardiac evaluation does not improve or predict perioperative or late survival in asymptomatic diabetic patients undergoing elective infrainguinal arterial reconstruction. J Vasc Surg 2005;41(1):38–45.

    Article  PubMed  Google Scholar 

  97. Mehat RH, Bossone E, Eagle KA. Perioperative cardiac risk assessment for noncardiac surgery. Cardiologia 1999;44:409–418.

    Google Scholar 

  98. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 1998;22:77–81.

    Article  PubMed  CAS  Google Scholar 

  99. Golden SH, Peart-Vigilance C, Kao L, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999;22:1408–1414.

    Article  PubMed  CAS  Google Scholar 

  100. Diabetic Foot Wound Care, consensus statement, American Diabetes Association. Diabetes Care 1999;22:1354–1360.

    Article  Google Scholar 

  101. Hopf JW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg 1997;132:997–1004.

    PubMed  CAS  Google Scholar 

  102. Greif R, Akca O, Horn HP, Kurtz A, Sessler DI. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med 2000;342:161–167.

    Article  PubMed  CAS  Google Scholar 

  103. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival MI in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Glucose Infusion in Acute MI) Study Group. BMJ 1997;314:1512–1515.

    PubMed  CAS  Google Scholar 

  104. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354(5):449–461.

    Article  PubMed  Google Scholar 

  105. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortman-nin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894–898.

    PubMed  CAS  Google Scholar 

  106. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:353–360.

    Article  Google Scholar 

  107. Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999;88:1011–1016.

    Article  PubMed  CAS  Google Scholar 

  108. Rümelin A, Nietgen M, Pirlich PT, et al. Postoperative pattern of various hormonal and metabolic variables. Curr Med Res Opin 1999;15:339–348.

    Article  PubMed  Google Scholar 

  109. Jacober SJ, Sowers JR. An update on perioperative management of diabetes. Arch Intern Med 1999;159:2405–2411.

    Article  PubMed  CAS  Google Scholar 

  110. Kaufman FR, Devgan S, Roe TF, Costin G. Perioperative management with prolonged intravenous insulin infusion versus subcutaneous insulin in children with type I diabetes mellitus. J Diabetes Complications 1996;10:6–11.

    Article  PubMed  CAS  Google Scholar 

  111. Husban DJ, Thai AC, Alberti KGMM. Management of diabetes during surgery with glucose-insulin-potassium infusion. Diabet Med 1986;3:69–74.

    Article  Google Scholar 

  112. Alberti KG, Gill GV, Elliott MJ. Insulin delivery during surgery in the diabetic patient. Diabetes Care 1982;5(Suppl 1):65–77.

    PubMed  Google Scholar 

  113. Clement S, Braithwaite SS, Magee MF, et al. American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27(2):553–591.

    Article  PubMed  Google Scholar 

  114. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925–927.

    Article  PubMed  CAS  Google Scholar 

  115. Garber AJ, Moghissi ES, Bransome ED Jr, et al. American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004;10(1):77–82.

    PubMed  Google Scholar 

  116. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997;157:545–552.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University, School of Medicine, New York

    Peter Sheehan MD (Associate Professor of Medicine (Clinical)

  2. Diabetes Foot and Ankle Center, New York, NY

    Peter Sheehan MD (Associate Professor of Medicine (Clinical)

Authors
  1. Peter Sheehan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Aristidis Veves MD, DSc , John M. Giurini DPM  & Frank W. Logerfo MD ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Sheehan, P. (2006). Introduction to Diabetes. In: Veves, A., Giurini, J.M., Logerfo, F.W. (eds) The Diabetic Foot. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59745-075-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-075-1_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-610-8

  • Online ISBN: 978-1-59745-075-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation